Chief Executive Officer
Johan Liwing has over 15 years’ experience from leading positions within the life sciences industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he held various positions in health economics, sales & marketing as well as observational research with increased responsibilities. In his last position at Janssen, as a Global Senior Director, he was responsible for developing the use of observational data. Johan Liwing has also worked for Roche as well as in other areas outside the life sciences industry, such as finance and engineering.
Chief Financial Officer
Hans Ericson is a Senior Finance professional with more than 20 years’ experience in international business and stock listed companies, with proven leadership in Controllership and Finance. He has had a number of leading positions primarily in Ericsson and Elekta, where he had the position as Group Controller for a long period of time. Hans has also been a consultant and have had assignments in various areas such as start-ups and large research organisations such as RISE.
Chief Medical Officer
Dr. Aschan received his MD from Karolinska Institutet (KI) in 1985 and his PhD in Clinical Immunology from KI in 1994. He has extensive experience from work within the field of allogenic stem cell transplantation at the Karolinska University Hospital in Huddinge, Sweden, and from various leadership roles within hematology and oncology at Janssen.
Most recently, prior to joining XNK, Dr. Aschan was Global Clinical Lead within Clinical Development at the Swedish biotech company Oncopeptides.
Markus Lagerlöf has an MSc in Industrial Engineering and Management from Linköping’s Technical University, Linköping, Sweden. He has more than 20 years of life sciences experience at Pfizer, Novartis, GSK, GE Healthcare and Sandoz within sales, marketing, strategy, M&A, business development and management. Since 2015, he is focusing on financing across the equity capital markets via Stockholm Corporate Finance AB. Markus has worked with global, regional and local responsibilities in New York, London, Munich, Stockholm and Uppsala.
Chief Scientific Officer
Professor Uhlin received his master’s degree in medical research with a focus on biomedicine from Karolinska Institutet (KI) in 2002 and his PhD in Infection Biology from KI in 2006. Since then, he has held several senior positions primarily within clinical immunology and cellular therapy at KI and Karolinska University Hospital, Stockholm, including serving as Head of Clinical Immunology, Department of Clinical Immunology and Transfusion Medicine at the Karolinska University Hospital.